-

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London.

A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours after the event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company develops transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel Prize-winning science of RNAi, achieving critical breakthroughs and bringing six medicines to approval. Its medicines are available in more than 70 countries, supported by a robust and rapidly expanding pipeline, and the Company is consistently recognized as an exceptional workplace and a socially responsible organization. Alnylam is executing its Alnylam 2030 strategy to accelerate innovation and scale its impact on human health. For more information, visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Contacts

Alnylam Pharmaceuticals, Inc.

Bo Piela
(Media)
508-308-9783

Josh Brodsky
(Investors)
617-551-8276

Industry:

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY
Release Versions
English

Contacts

Alnylam Pharmaceuticals, Inc.

Bo Piela
(Media)
508-308-9783

Josh Brodsky
(Investors)
617-551-8276

More News From Alnylam Pharmaceuticals, Inc.

Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi...

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2026, and reviewed recent business highlights. “Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “As we co...

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (...
Back to Newsroom